stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) Revenue
ImmunityBio, Inc.'s revenue for fiscal 2025 was $113.3M, up 668.3% from $14.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was $165.8M. Over the past ten years it has ranged from $44.0K (fiscal 2016) to $113.3M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 3 consecutive fiscal years. ImmunityBio, Inc. ranks 75th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $113.3M | 668.31% |
| FY2024 | $14.7M | 2,270.58% |
| FY2023 | $622.0K | 159.17% |
| FY2022 | $240.0K | (74.30%) |
| FY2021 | $934.0K | 54.38% |
| FY2020 | $605.0K | (72.52%) |
| FY2019 | $2.2M | 4,585.11% |
| FY2018 | $47.0K | 4.44% |
| FY2017 | $45.0K | 2.27% |
| FY2016 | $44.0K | (81.36%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $51.2M | 15.91% |
| Mar 2026 | $44.2M | 15.47% |
| Dec 2025 | $38.3M | 19.41% |
| Sep 2025 | $32.1M | 21.33% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MDGL Madrigal Pharmaceuticals, Inc. compare | $1.4B |
| CAI Caris Life Sciences,�Inc. compare | $1.0B |
| TGTX TG Therapeutics, Inc. compare | $799.5M |
| KRYS Krystal Biotech, Inc. compare | $470.0M |
| TWST Twist Bioscience Corporation compare | $431.8M |
| PTGX Protagonist Therapeutics, Inc. compare | $282.0M |
| IBRX ImmunityBio, Inc. | $165.8M |
| CYTK Cytokinetics, Incorporated compare | $113.3M |
| SYRE Spyre Therapeutics, Inc. compare | $1.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on IBRX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement